Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.30 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29775354 | 0.81 | HTR2A (0.45) | HTR2AHTR2CNOTUMCYP11B1CYP11B2 | |
| SCHEMBL23326300 | 0.81 | HTR2A (0.45) | HTR2AHTR2CNOTUMCYP11B1CYP11B2 | |
| SCHEMBL31167218 | 0.81 | ALDH1A1 (0.34) | HTR2AHTR2CKDM4EALDH1A1MAPT | |
| SCHEMBL31335940 | 0.81 | KDM4E (0.32) | HTR2AKDM4EALDH1A1MAPT | |
| SCHEMBL4520961 | 0.77 | HTR2A (0.33) | HTR2AHTR2CKDM4EALDH1A1MAPT | |
| SCHEMBL29447054 | 0.77 | HTR2A (0.33) | HTR2AHTR2CKDM4EALDH1A1MAPT | |
| SCHEMBL15980355 | 0.76 | HTR2A (0.39) | HTR2AHTR2CKDM4EALDH1A1MAPT | |
| SCHEMBL26932098 | 0.75 | HTR2A (0.42) | HTR2AHTR2CKDM4EALDH1A1MAPT | |
| SCHEMBL25338016 | 0.74 | NOTUM (0.33) | HTR2AHTR2CNOTUM | |
| SCHEMBL29490991 | 0.74 | NOTUM (0.33) | HTR2AHTR2CNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2023003002-A1 | ANNULATED PYRIDAZINE COMPOUND | アステラス製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | HTR2A 493/4885HTR2C 988/4885NOTUM 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.